# Wolverine Legal Status, FDA 503A Category, and Compounding Access (BPC-157 TB-500)

> Wolverine legal status for the BPC-157 TB-500 blend: both peptides sit in FDA's 503A Category 2 — compounding access restricted now — with both under active FDA review at a scheduled July 2026 meeting. Cited to FDA.

Where the BPC-157 TB-500 blend stands now — and where the record is moving. General information about the regulatory landscape, cited to FDA. Not medical or legal advice.

## Wolverine legal status: momentum, and where the FDA 503A record stands now

The Wolverine legal status question turns on its two peptides, and the record on those peptides is in motion — there is real momentum, and compounding access may expand in 2026. The anchor for that momentum is concrete and dated: an FDA Pharmacy Compounding Advisory Committee (PCAC) meeting is scheduled for July 23-24, 2026 to discuss these peptides as candidates for the Section 503A bulks list [14].

That forward motion sits on top of a present-tense fact that has not changed. Both of Wolverine's constituents — BPC-157 and TB-500 — are currently in FDA's 503A "Category 2," bulk drug substances FDA has identified as potentially presenting significant safety risks. That placement took effect with the September 29, 2023 update to FDA's nominated-substances list, and Category 2 substances are not within FDA's enforcement-discretion policy for 503A compounding [12]. In plain terms, compounding-pharmacy access to these peptides is restricted as the record stands today.

Nothing here states that any reclassification has happened. The July 2026 meeting is a scheduled discussion of substances under evaluation — a step in the process, not a decision, a listing, or a settled outcome [14]. This page is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply anything.

## What "Category 2" means under Sections 503A and 503B

Two sections of the Federal Food, Drug, and Cosmetic Act govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight [13].

A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Substances not yet listed are evaluated through a public nomination process, with input from the PCAC [13].

Under FDA's interim policy, Category 2 bulk drug substances are those nominated with enough information to evaluate but which FDA identified as raising significant safety risks. Category 2 is not covered by the enforcement-discretion policy that applies to Category 1, and FDA stated it would consider taking action against a compounder using a Category 2 substance [12]. On January 7, 2025, FDA finalized a revised interim policy under which it no longer sorts newly nominated substances into these numbered categories; substances already in Category 2 are not afforded enforcement discretion even if nominations are updated [13]. FDA approval of a finished drug is a separate question from compounding eligibility, and neither BPC-157 nor TB-500 is an FDA-approved drug [13].

## Both Wolverine peptides are under review — and there is no component carve-out

Both of Wolverine's components are on the July 2026 agenda — there is no component exception. FDA's public calendar lists BPC-157 and TB-500 (alongside KPV and MOTS-c) as bulk drug substances "being considered for inclusion on the 503A Bulks List" at the scheduled July 23-24, 2026 PCAC meeting [14].

That means the entire Wolverine pairing is currently Category 2 and the entire pairing is under this one scheduled review. BPC-157 appears as "BPC-157 (free base)" and "BPC-157 acetate" [12]. TB-500 is the substance FDA lists as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — FDA's own entry establishes that the marketed TB-500 is the LKKTETQ fragment of thymosin beta-4, the same fragment described throughout this site [12]. Both placements took effect with the September 29, 2023 list update, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide impurities and active-ingredient characterization [12].

Being discussed by PCAC is a step in evaluation, not a final listing decision, and the outcome of the meeting is unknown — no result should be assumed or dated [14].

## How legally compounded peptide access works

In the U.S., a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [13]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility [13].

Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It is one route to a licensed-prescriber consultation — not a separate legal status. Telehealth does not expand which substances may be compounded, and it does not remove the need for a legitimate clinical evaluation and a valid prescription [13].

The ingredient-eligibility caveat is the part that matters most for these two peptides. A compounded preparation may lawfully be made only when its active ingredient is permitted under the 503A/503B framework — a USP/NF monograph, a component of an approved drug, or a place on the applicable FDA bulks list. Ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands [13]. As the record stands today, that is where BPC-157 and TB-500 sit. This page names no pharmacy, clinic, telehealth provider, or vendor, and offers no dosing, administration instructions, or means of obtaining a restricted substance outside the lawful framework.

## WADA-prohibited status in sport

Outside the compounding question, both constituents are prohibited in sport. The World Anti-Doping Agency prohibits BPC-157 under its S0 non-approved-substances category, and TB-500 / thymosin beta-4 falls under prohibited peptide, growth-factor, and tissue-repair categories. The blend is banned in and out of competition for the relevant classes. This is a sport-eligibility fact, separate from the FDA compounding status above, and it is included here because tested athletes are among the people who search for the pairing.

## Is the Wolverine Blend Legal?

Neither BPC-157 nor TB-500 is an FDA-approved drug for human use, and the Wolverine blend has no approved therapeutic indication [12][13]. Both constituents are currently in FDA's 503A Category 2 — bulk drug substances FDA has identified as potentially presenting significant safety risks — so routine compounding-pharmacy access is restricted as the record stands [12]. Both are also prohibited in sport by WADA. The lawful compounding pathway requires a licensed-prescriber evaluation and a valid, patient-specific prescription, subject to the ingredient-eligibility rules above [13].

## Can BPC-157 Be Obtained From a Compounding Pharmacy?

As the record stands, BPC-157 is in FDA's 503A Category 2 — identified as a bulk drug substance that may present significant safety risks, effective with the September 29, 2023 list update — and Category 2 substances are not within FDA's enforcement-discretion policy for 503A compounding [12]. That restricts routine compounding-pharmacy access to BPC-157 now. BPC-157 is also on the scheduled July 23-24, 2026 PCAC agenda as a candidate for the 503A bulks list, which is a scheduled evaluation and not a change in its current status [14].

## What Is the FDA 503A Status of the Wolverine Components?

Both of Wolverine's constituents are unapproved research substances, and the blend is not an approved drug anywhere [12][13]. BPC-157 and TB-500 are each currently in FDA's 503A Category 2, effective with the September 29, 2023 nominated-substances list update [12]. Both are also on the scheduled July 23-24, 2026 PCAC agenda as substances "being considered for inclusion on the 503A Bulks List" — a discussion of candidates under evaluation, not a listing decision or a reclassification [14]. There is no component carve-out: the pairing is Category 2 today, and both halves sit under the same scheduled review.

---

A distilled field-record of the BPC-157 and TB-500 literature — each peptide pressed as its own cited specimen, its 503A access status read first, with no clinic behind the folio and nothing here prescribed or sold.